Larkberget

Larkberget Enterprise Value

The Enterprise Value (EV) of Larkberget (LARK.ST) as of Oct 16, 2026 is 42.87 M SEK. In the previous year, Enterprise Value (EV) was -25.04 M SEK — a change of -271.22% (higher).

Enterprise Value

42.87 MSEK

YoY

-271.22%

Last updated:

Enterprise Value (EV) of Larkberget is 2025 42.87 M SEK. Enterprise Value (EV) of Larkberget was 2024 -25.04 M SEK. It decreases by -271.22% higher compared to the previous year.

The Larkberget Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
16.91 M SEK
Jan 1, 2019
42.55 M SEK
Jan 1, 2020
-184,300.00 SEK
Jan 1, 2021
-88.03 M SEK
Jan 1, 2022
-83.07 M SEK
Jan 1, 2023
-52.73 M SEK
Jan 1, 2024
-25.04 M SEK
Jan 1, 2025
42.87 M SEK
The Larkberget Enterprise Value history
YEAREnterprise ValueYoY
42.87 MSEK-271.22%
-25.04 MSEK-52.52%
-52.73 MSEK-36.52%
-83.07 MSEK-5.64%
-88.03 MSEK+47,666.06%
-184,300.00SEK-100.43%
42.55 MSEK+151.65%
16.91 MSEK-61.39%
43.79 MSEK-4.08%
45.66 MSEK+16.07%
39.33 MSEK-9.61%
43.52 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? Larkberget AB, trading under the ticker LARK.ST, is a biotechnology company based in Lidingoe, Sweden. The company, which is listed on the Stockholm Stock Exchange, went public through an IPO on May 25, 2015. Larkberget AB operates within the health care sector, specifically in the biotechnology industry. The company's website is https://combigene.com/. According to the provided information, Larkberget AB is engaged in the development of new treatments for neurological diseases. The firm's platform involves the use of gene therapy vectors to deliver combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. These vectors are designed for the treatment of neurological and psychiatric diseases in both humans and animals. The company focuses on developing an epilepsy treatment using an adeno-associated virus (AAV) vector that carries transgenes for the neurotransmitter NPY and its receptor, the G protein-coupled receptor Y2. The company's headquarters are located in Lidingoe, near Stockholm. Larkberget is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Larkberget stock

Enterprise Value (EV) of Larkberget is 42.87 M SEK in 2025.

Enterprise Value (EV) of Larkberget changed from -25.04 M SEK to 42.87 M SEK, representing a -271.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Larkberget since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s SEK, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' SEK varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Larkberget with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Larkberget

All Key Metrics — Larkberget